Table 3

Baseline characteristics and clinical characteristics after 4 months of patients achieving remission versus patients not achieving remission

RemissionNo remission
BaselineN=375N=221p Value
DAS (mean, SD)2.99 (0.85)3.57 (0.92)<0.001
Swollen joint count5 (2–9)7 (3–12)0.001
Tender joint count5 (3–8)8 (6–14)<0.001
VAS general health, mm (mean, SD)42 (24)52 (21)<0.001
ESR mm/h (median, IQR)23 (10–38)25 (13–41)0.20
HAQ (mean, SD)1.03 (0.65)1.37 (0.62)<0.001
Small joints* (median, IQR)8 (4–13)12 (7–18)<0.001
Large joints (median, IQR)1 (0–2)2 (1–4)<0.001
Age, years (mean, SD)52 (14)51 (14)0.54
Symptom duration, weeks (median, IQR)16 (9–30)21 (9–37)0.08
Female no. (%)231 (62)172 (78)<0.001
RF positive no. (%)219 (58)111 (50)0.09
ACPA positive no. (%)220 (59)106 (48)0.007
Diagnosis RA (2010) no. (%)291 (78)177 (80)0.46
BMI25.4 (3.9)26.6 (5.1)0.001
Follow-up (4 months)
DAS (mean, SD)0.94 (0.36)2.45 (0.65)<0.001
Swollen joint count0 (0–0)1 (0–4)<0.001
Tender joint count0 (0–1)4 (3–8)<0.001
VAS general health, mm (mean, SD)13 (14)36 (21)<0.001
ESR mm/h (median, IQR)6 (3–13)11 (6–22)<0.001
HAQ (mean, SD)0.23 (0.33)0.82 (0.59)<0.001
  • * Number of swollen and/or tender small joints (metacarpophalangeal joints, proximal interphalangeal joints, thumb interphalangeal joints, wrists, second through fifth metacarpophalangeal joints).

  • Number of swollen and/or tender large joints (shoulders, elbows, hips, knees, ankles).

  • ACPA, anticitrullinated protein antibodies; BMI, body mass index; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; RA, rheumatoid arthritis; RF, rheumatoid factor; VAS, Visual Analogue Scale.

  • DAS at 4 months was missing in two patients.